WellCare upgraded to Outperform from Neutral at Credit Suisse Credit Suisse upgraded WellCare due to favorable risk/reward, favorable Medicaid and Medicare growth trends, and believes takeout potential provides support. Price target lowered to $70 from $77.
News For WCG From The Last 14 Days
Check below for free stories on WCG the last two weeks.
WellCare downgraded at Wedbush As noted earlier, Wedbush downgraded WellCare to Neutral from Outperform. The firm no longer sees the company as a takeover candidate, and it thinks that the company will need at least 2-3 years to turn itself around. Target to $55 from $70.